Company news

Altimmune, Inc. news in 2025

Altimmune, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

December 19, 2025

Altimmune Announces CEO Transition and Succession Plan

December 1, 2025

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 26, 2025

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

November 11, 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

November 7, 2025

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

November 6, 2025

Altimmune to Participate in Two Upcoming Investor Conferences

November 5, 2025

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

November 3, 2025

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

October 30, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

October 19, 2025

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

September 29, 2025

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

September 15, 2025

Altimmune to Participate in Upcoming Investor Conferences

August 26, 2025

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

August 19, 2025

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

August 12, 2025

Altimmune Board of Directors Appoints Jerry Durso as Chairman

August 11, 2025

Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

August 5, 2025

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

July 9, 2025

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

June 26, 2025

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

June 25, 2025

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions

June 13, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

May 19, 2025

Altimmune to Participate at Two Upcoming Investor Conferences

May 14, 2025

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

May 13, 2025

Altimmune Announces First Quarter 2025 Financial Results and Business Update

May 13, 2025

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

May 8, 2025

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

May 6, 2025

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

May 1, 2025

Altimmune to Participate in the Citizens Life Sciences Conference

April 30, 2025

Altimmune to Host Virtual R&D Day on March 13, 2025

March 6, 2025

Altimmune to Participate in the Leerink Global Healthcare Conference

March 3, 2025

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

February 27, 2025

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

February 25, 2025

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

February 20, 2025

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

January 28, 2025

Calls in 2025

Decks in 2025